Humanization and epitope mapping of the H23 anti-MUC1 monoclonal antibody reveals a dual epitope specificity

Molecular Immunology

Volumn 42, Issue 1, 2005, Pages 55-69

  Mazor, Yariv ^a   Keydar, Iafa ^a   Benhar, Itai ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Epitope mapping; Humanization; Monoclonal antibody; MUC1; Reverse DIP; scFv

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; MALTOSE BINDING PROTEIN; MONOCLONAL ANTIBODY; MUCIN 1; MUCIN 1 ANTIBODY; PEPTIDE LIBRARY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EPITOPE MAPPING; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RANDOMIZATION; TANDEM REPEAT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; BASE SEQUENCE; BINDING, COMPETITIVE; BREAST NEOPLASMS; CARRIER PROTEINS; CLONING, MOLECULAR; EPITOPE MAPPING; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MICE; MOLECULAR SEQUENCE DATA; MUCINS; PEPTIDE LIBRARY; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS;

ESCHERICHIA COLI; MURINAE;

EID: 5444232121     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2004.07.013     Document Type: Article

References (70)

1. B. Al-Lazikani, A.M. Lesk, and C. Chothia Standard conformations for the canonical structures of immunoglobulins J. Mol. Biol. 273 1997 927 948
2. R. Azriel-Rosenfeld, M. Valensi, and I. Benhar A Human Synthetic Combinatorial Library of arrayable single-chain antibodies based on shuffling in vivo formed CDRs into general framework regions J. Mol. Biol. 335 2004 177 192
3. H. Bach, Y. Mazor, S. Shaky, A. Shoham-Lev, Y. Berdichevsky, D.L. Gutnick, and I. Benhar Escherichia coli maltose-binding protein as a molecular chaperone for recombinant intracellular cytoplasmic single-chain antibodies J. Mol. Biol. 312 2001 79 93 doi:10.1006/jmbi.2001.4914
4. T.S. Baker, C.C. Bose, H.M. Caskey-Finney, D.J. King, A.D. Lawson, A. Lyons, A. Mountain, R.J. Owens, M.R. Rolfe, and M. Sehdev Humanization of an anti-mucin antibody for breast and ovarian cancer therapy Adv. Exp. Med. Biol. 353 1994 61 82
5. S.E. Baldus, D. Goergen, F.G. Hanisch, and H.P. Dienes Epitope-dependent differential immunoreactivities of anti-MUC1 monoclonal antibodies in human carcinomas Int. J. Oncol. 18 2001 507 512
6. S.M. Barratt-Boyes Making the most of mucin: a novel target for tumor immunotherapy Cancer Immunol. Immunother. 43 1996 142 151
7. A. Baruch, M. Hartmann, M. Yoeli, Y. Adereth, S. Greenstein, Y. Stadler, Y. Skornik, J. Zaretsky, N.I. Smorodinsky, I. Keydar, and D.H. Wreschner The breast cancer-associated MUC1 gene generates both a receptor and its cognate-binding protein Cancer Res. 59 1999 1552 1561
8. I. Benhar, R. Azriel, L. Nahary, S. Shaky, Y. Berdichevsky, A. Tamarkin, and W. Wels Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA' fusions on live bacteria J. Mol. Biol. 301 2000 893 904
9. I. Benhar, E.A. Padlan, S.H. Jung, B. Lee, and I. Pastan Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38 Proc. Natl. Acad. Sci. USA 91 1994 12051 12055
10. I. Benhar, and Y. Reiter Phage display of single-chain antibodies J. Colligan Current Protocols in Immunology Vol. 10.19B Wiley 2001 10.19B.1 10.19B.30
11. Y. Berdichevsky, E. Ben-Zeev, R. Lamed, and I. Benhar Phage display of a cellulose-binding domain from Clostridium thermocellum and its application as a tool for antibody engineering J. Immunol. Methods 228 1999 151 162
12. I. Bieche, and R. Lidereau A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors Cancer Genet. Cytogenet. 98 1997 75 80
13. A. Blockzjil, K. Nilsson, and O. Nilsson Epitope characterization of MUC1 antibodies Tumor Biol. 19 Suppl. 1 1998 46 56
14. S.Y. Chan, A.N. Gordon, R.E. Coleman, J.B. Hall, M.S. Berger, M.L. Sherman, C.B. Eten, and N.J. Finkler A phase 2 study of the cytotoxic immunoconjugate CMB-401 (HCTM01-calicheamicin) in patients with platinum-sensitive recurrent epithelial ovarian carcinoma Cancer Immunol. Immunother. 52 2003 243 248
15. C. Chothia, and A.M. Lesk Canonical structures for the hypervariable regions of immunoglobulins J. Mol. Biol. 196 1987 901 917
16. R. Cortese, F. Felici, G. Galfre, A. Luzzago, P. Monaci, and A. Nicosia Epitope discovery using peptide libraries displayed on phage Trends Biotechnol. 12 1994 262 267
17. J.R. Couto, R.B. Christian, J.A. Peterson, and R.L. Ceriani Designing human consensus antibodies with minimal positional templates Cancer Res. 55 1995 5973s 5977s
18. J.R. Couto, E.A. Padlan, E.W. Blank, J.A. Peterson, and R.L. Ceriani Humanization of KC4G3, an anti-human carcinoma antibody Hybridoma 13 1994 215 219
19. M.V. Croce, M.T. Isla-Larrain, S.O. Demichelis, J.R. Gori, M.R. Price, and A. Segal-Eiras Tissue and serum MUC1 mucin detection in breast cancer patients Breast Cancer Res. Treat. 81 2003 195 207
20. P.S. Daugherty, M.J. Olsen, B.L. Iverson, and G. Georgiou Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface Protein Eng. 12 1999 613 621
21. H.J. de Haard, B. Kazemier, A. van der Bent, P. Oudshoorn, P. Boender, B. van Gemen, J.W. Arends, and H.R. Hoogenboom Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding Protein Eng. 11 1998 1267 1276
22. H.J. de Haard, N. van Neer, A. Reurs, S.E. Hufton, R.C. Roovers, P. Henderikx, A.P. de Bruine, J.W. Arends, and H.R. Hoogenboom A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies J. Biol. Chem. 274 1999 18218 18230
23. S.J. DeNardo, E.L. Kramer, R.T. O'Donnell, C.M. Richman, Q.A. Salako, S. Shen, M. Noz, S.D. Glenn, R.L. Ceriani, and G.L. DeNardo Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial J. Nucl. Med. 38 1997 1180 1185
24. G. Denton, K. Brady, B.K. Lo, A. Murray, C.R. Graves, O.D. Hughes, S.J. Tendler, C.A. Laughton, and M.R. Price Production and characterization of an anti-(MUC1 mucin) recombinant diabody Cancer Immunol. Immunother. 48 1999 29 38
25. A.S. Dion, N.I. Smorodinsky, C.J. Williams, D.H. Wreschner, P.P. Major, and I. Keydar Recognition of peptidyl epitopes by polymorphic epithelial mucin (PEM)-specific monoclonal antibodies Hybridoma 10 1991 595 610
26. D. Enshell-Seijffers, L. Smelyanski, and J.M. Gershoni The rational design of a 'type 88' genetically stable peptide display vector in the filamentous bacteriophage fd Nucleic Acids Res. 29 2001 E50-0
27. F. Felici, A. Luzzago, P. Monaci, A. Nicosia, M. Sollazzo, and C. Traboni Peptide and protein display on the surface of filamentous bacteriophage Biotechnol. Annu. Rev. 1 1995 149 183
28. S. Fiorentini, E. Matczak, R.C. Gallo, M.S. Reitz, I. Keydar, and B.A. Watkins Humanization of an antibody recognizing a breast cancer specific epitope by CDR-grafting Immunotechnology 3 1997 45 59
29. A. Folgori, R. Tafi, A. Meola, F. Felici, G. Galfre, R. Cortese, P. Monaci, and A. Nicosia A general strategy to identify mimotopes of pathological antigens using only random peptide libraries and human sera Embo J. 13 1994 2236 2243
30. G. Froyen, D. Hendrix, I. Ronsse, P. Fiten, E. Martens, and A. Billiau Effect of VH and VL consensus sequence-specific primers on the binding and neutralizing potential of a single-chain FV directed towards HuIFN-gamma Mol. Immunol. 32 1995 515 521
31. S.J. Gendler, C.A. Lancaster, J. Taylor-Papadimitriou, T. Duhig, N. Peat, J. Burchell, L. Pemberton, E.N. Lalani, and D. Wilson Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin J. Biol. Chem. 265 1990 15286 15293
32. A.M. Gillespie, T.J. Broadhead, S.Y. Chan, J. Owen, A.P. Farnsworth, M. Sopwith, and R.E. Coleman Phase I open study of the effects of ascending doses of the cytotoxic immunoconjugate CMB-401 (hCTMO1-calicheamicin) in patients with epithelial ovarian cancer Ann. Oncol. 11 2000 735 741
33. M. Hakoda, N. Kamatani, S. Hayashimoto-Kurumada, G.J. Silverman, H. Yamanaka, C. Terai, and S. Kashiwazaki Differential binding avidities of human IgM for staphylococcal protein A derive from specific germ-line VH3 gene usage J. Immunol. 157 1996 2976 2981
34. M. Hareuveni, I. Tsarfaty, J. Zaretsky, P. Kotkes, J. Horev, S. Zrihan, M. Weiss, S. Green, R. Lathe, and I. Keydar A transcribed gene, containing a variable number of tandem repeats, codes for a human epithelial tumor antigen cDNA cloning, expression of the transfected gene and over-expression in breast cancer tissue Eur. J. Biochem. 189 1990 475 486
35. P. Henderikx, N. Coolen-van Neer, A. Jacobs, E. van der Linden, J.W. Arends, J. Mullberg, and H.R. Hoogenboom A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized Am. J. Pathol. 160 2002 1597 1608
36. P. Henderikx, M. Kandilogiannaki, C. Petrarca, S. von Mensdorff-Pouilly, J.H. Hilgers, E. Krambovitis, J.W. Arends, and H.R. Hoogenboom Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma Cancer Res. 58 1998 4324 4332
37. A. Honegger, and A. Plückthun The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains J. Mol. Biol. 309 2001 687 699
38. Jirholt, P., Ohlin, M., Borrebaeck, C.A.K., Soderlind, E., 1998. Exploiting sequence space: shuffling in vivo formed complementarity determining regions into a master framework. Gene 215, 471-476, doi:10.1016/S0378-1119(98) 00317-5.
39. S. Jung, S. Spinelli, B. Schimmele, A. Honegger, L. Pugliese, C. Cambillau, and A. Plückthun The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains J. Mol. Biol. 309 2001 701 716
40. I. Keydar, C.S. Chou, M. Hareuveni, I. Tsarfaty, E. Sahar, G. Selzer, S. Chaitchik, and A. Hizi Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens Proc. Natl. Acad. Sci. USA 86 1989 1362 1366
41. B. Kong, W. Wang, C. Liu, L. Song, D. Ma, X. Qu, J. Jiang, X. Yang, Y. Zhang, B. Wang, M.Q. Wei, and Q. Yang Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer In Vivo 17 2003 153 156
42. A. Krebber, S. Bornhauser, J. Burmester, A. Honegger, J. Willuda, H.R. Bosshard, and A. Plückthun Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system J. Immunol. Methods 201 1997 35 55
43. I.L. Laisney, and A.D. Strosberg Dual specificity of a human neutralizing monoclonal antibody, specific for the V3 loop of GP120 (HIV-1) Immunol. Lett. 67 1999 185 192
44. A.C. Langedijk, A. Honegger, J. Maat, R.J. Planta, R.C. van Schaik, and A. Plückthun The nature of antibody heavy chain residue H6 strongly influences the stability of a VH domain lacking the disulfide bridge J. Mol. Biol. 283 1998 95 110
45. J. Li, Y. Wang, Z. Wang, and Z. Dong Influences of amino acid sequences in FR1 region on binding activity of the scFv and Fab of an antibody to human gastric cancer cells Immunol. Lett. 71 2000 157 165
46. A. Maraveyas, D. Snook, V. Hird, C. Kosmas, C.F. Meares, H.E. Lambert, and A.A. Epenetos Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer Cancer 73 1994 1067 1075
47. A. Martoni, C. Zamagni, B. Bellanova, L. Zanichelli, F. Vecchi, N. Cacciari, E. Strocchi, and F. Pannuti CEA, MCA, CA 15. 3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study Eur. J. Cancer 31A 1995 1615 1621
48. V. Morea, A. Tramontano, M. Rustici, C. Chothia, and A.M. Lesk Conformations of the third hypervariable region in the VH domain of immunoglobulins J. Mol. Biol. 275 1998 269 294
49. A. Mountain, and J.R. Adair Engineering antibodies for therapy Biotechnol. Genet. Eng. Rev. 10 1992 1 142
50. S. O'Brien, and T. Jones Humanization of monoclonal antibodies by CDR grafting Methods Mol. Biol. 207 2003 81 100
51. B. Oliva, P.A. Bates, E. Querol, F.X. Aviles, and M.J. Sternberg Automated classification of antibody complementarity determining region 3 of the heavy chain (H3) loops into canonical forms and its application to protein structure prediction J. Mol. Biol. 279 1998 1193 1210
52. S. Paul, D. Snary, J. Hoebeke, D. Allen, J.M. Balloul, N. Bizouarne, K. Dott, M. Geist, J. Hilgers, M.P. Kieny, J. Burchell, J. Taylor-Papadimitriou, and R.B. Acres Targeted macrophage cytotoxicity using a non-replicative live vector expressing a tumor-specific single-chain variable region fragment Hum. Gene Ther. 11 2000 1417 1428
53. G.A. Pietersz, L. Wenjun, K. Krauer, T. Baker, D. Wreschner, and I.F. McKenzie Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy Cancer Immunol. Immunother. 44 1997 323 328
54. M.R. Price, P.D. Rye, E. Petrakou, A. Murray, K. Brady, S. Imai, S. Haga, Y. Kiyozuka, D. Schol, M.F. Meulenbroek, F.G. Snijdewint, S. von Mensdorff-Pouilly, R.A. Verstraeten, P. Kenemans, A. Blockzjil, K. Nilsson, O. Nilsson, M. Reddish, M.R. Suresh, R.R. Koganty, S. Fortier, L. Baronic, A. Berg, M.B. Longenecker, and J. Hilgers Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17-23, 1996 Tumor Biol. 19 Suppl. 1 1998 1 20
55. H.M. Prinssen, C.F. Molthoff, R.H. Verheijen, T.J. Broadhead, P. Kenemans, J.C. Roos, Q. Davies, A.C. van Hof, M. Frier, W. den Hollander, A.J. Wilhelm, T.S. Baker, M. Sopwith, E.M. Symonds, and A.C. Perkins Biodistribution of 111In-labelled engineered human antibody CTM01 (hCTM01) in ovarian cancer patients: influence of prior administration of unlabelled hCTM01 Cancer Immunol. Immunother. 47 1998 39 46
56. C.M. Richman, and S.J. DeNardo Systemic radiotherapy in metastatic breast cancer using 90Y-linked monoclonal MUC-1 antibodies Crit. Rev. Oncol. Hematol. 38 2001 25 35
57. L. Riechmann, M. Clark, H. Waldmann, and G. Winter Reshaping human antibodies for therapy Nature 332 1988 323 327
58. N. Sakurai, T. Kudo, M. Suzuki, K. Tsumoto, S. Takemura, H. Kodama, S. Ebara, A. Teramae, Y. Katayose, M. Shinoda, T. Kurokawa, Y. Hinoda, K. Imai, S. Matsuno, and I. Kumagai SEA-scFv as a bifunctional antibody: construction of a bacterial expression system and its functional analysis Biochem. Biophys. Res. Commun. 256 1999 223 230
59. J. Samuel, and B.M. Longenecker Development of active specific immunotherapeutic agents based on cancer-associated mucins Pharm. Biotechnol. 6 1995 875 890
60. J.E. Shively The chemistry of protein sequence analysis Exs 88 2000 99 117
61. S.S. Sidhu, W.J. Fairbrother, and K. Deshayes Exploring protein-protein interactions with phage display Chembiochemistry 4 2003 14 25
62. I.I. Singer, D.W. Kawka, J.A. DeMartino, B.L. Daugherty, K.O. Elliston, K. Alves, B.L. Bush, P.M. Cameron, G.C. Cuca, and P. Davies Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework sequences J. Immunol. 150 1993 2844 2857
63. R.G. Smith, S. Missailidis, and M.R. Price Purification of anti-MUC1 antibodies by peptide mimotope affinity chromatography using peptides derived from a polyvalent phage display library J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 766 2002 13 26
64. J. Taylor-Papadimitriou, J. Burchell, D.W. Miles, and M. Dalziel MUC1 and cancer Biochim. Biophys. Acta 1455 1999 301 313
65. J. Taylor-Papadimitriou, and A.A. Epenetos Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy Trends Biotechnol. 12 1994 227 233
66. M. Verma Carcinoma-associated mucins: molecular biology and clinical applications Cancer Biochem. Biophys. 14 1994 151 162
67. B.A. Watkins, A.E. Davis, S. Fiorentini, and M.S. Reitz Jr. V-region and class specific RT-PCR amplification of human immunoglobulin heavy and light chain genes from B-cell lines Scand. J. Immunol. 42 1995 442 448
68. M.D. Winthrop, S.J. DeNardo, H. Albrecht, G.R. Mirick, L.A. Kroger, K.R. Lamborn, C. Venclovas, M.E. Colvin, P.A. Burke, and G.L. DeNardo Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy Clin. Cancer Res. 9 2003 3845S 3853S
69. C.J. Workman, W.P. Pfund, and E.W. Voss Jr. Dual specificity and the formation of stable autoimmune complexes J. Mol. Recognit. 10 1997 225 234
70. C.J. Workman, W.P. Pfund, and E.W. Voss Jr. Two dual-specific (anti-IgG and anti-dsDNA) monoclonal autoantibodies derived from the NZB/NZW F1 recognize an epitope in the hinge region J. Protein Chem. 17 1998 599 606